Big Pharma May Be Big Player in Follow-On Biologics Market
This article is a reprint from the April 2008 issue of The RPM Report. As Congress works on an approval pathway for follow-on biologics, generic drug companies are jockeying for investors' attention. But given that most generic manufacturers may be ill-equipped to handle the development of follow-on proteins, some analysts think the real opportunity is where you'd least expect: inside Big Pharma and biotech.
You may also be interested in...
Merck’s Ambitious Plans For Follow-On Biologics
Merck outlined ambitious plans for launching and growing a follow-on biologics business during its annual business briefing Dec. 9
Turning Back the Clock: Drug Approvals Hit 25 Year Low
You have to go back to 1983 to find a year as bad as 2007 for R&D output. It was a terrible year by any measure. The key question for industry: does it need to learn to subsist on a trickle of new drugs coming to market each year, or is the current drought in fact a sign of a transition to a new, more innovative R&D model? The sparse class of 2007 does offer some glimmers of hope.
Flubbing the FOBs Opportunity: Follow-on Biologics Winners & Losers
An abbreviated pathway for follow-on biologics just missed getting tacked onto the FDA user fee/drug reform legislation. It will be years before proponents get another shot at creating an abbreviated approval pathway for the biotech copycats. So who won and who lost?